Open AccessS220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS
Author(s) -
Dickinson M.,
CarloStella C.,
Morschhauser F.,
Bachy E.,
Corradini P.,
Iacoboni G.,
Khan C.,
Wróbel T.,
Offner F.,
Trněný M.,
Wu S.J.,
Cartron G.,
Hertzberg M.,
Sureda A.,
PerezCallejo D.,
Lundberg L.,
Relf J.,
Clark E.,
Humphrey K.,
Hutchings M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843772.15634.49
Subject(s) - medicine , diffuse large b cell lymphoma , follicular lymphoma , cytokine release syndrome , lymphoma , rituximab , gastroenterology , refractory (planetary science) , clinical endpoint , oncology , cancer , clinical trial , immunotherapy , biology , chimeric antigen receptor , astrobiology